关注
Olli Dufva
Olli Dufva
在 helsinki.fi 的电子邮件经过验证
标题
引用次数
引用次数
年份
Integrated drug profiling and CRISPR screening identify essential pathways for CAR T-cell cytotoxicity
O Dufva, J Koski, P Maliniemi, A Ianevski, J Klievink, J Leitner, P Pölönen, ...
Blood, The Journal of the American Society of Hematology 135 (9), 597-609, 2020
1732020
Immunogenomic landscape of hematological malignancies
O Dufva, P Pölönen, O Brück, MAI Keränen, J Klievink, J Mehtonen, ...
Cancer Cell 38 (3), 380-399. e13, 2020
1472020
Phenotype-based drug screening reveals association between venetoclax response and differentiation stage in acute myeloid leukemia
H Kuusanmäki, AM Leppä, P Pölönen, M Kontro, O Dufva, D Deb, ...
Haematologica 105 (3), 708, 2020
1352020
Aggressive natural killer-cell leukemia mutational landscape and drug profiling highlight JAK-STAT signaling as therapeutic target
O Dufva, M Kankainen, T Kelkka, N Sekiguchi, SA Awad, S Eldfors, ...
Nature communications 9 (1), 1567, 2018
1302018
Implementing a functional precision medicine tumor board for acute myeloid leukemia
D Malani, A Kumar, O Brück, M Kontro, B Yadav, M Hellesøy, ...
Cancer discovery 12 (2), 388-401, 2022
912022
Immune cell contexture in the bone marrow tumor microenvironment impacts therapy response in CML
O Brück, S Blom, O Dufva, R Turkki, H Chheda, A Ribeiro, P Kovanen, ...
Leukemia 32 (7), 1643-1656, 2018
912018
Discovery of novel drug sensitivities in T-PLL by high-throughput ex vivo drug testing and mutation profiling
EI Andersson, S Pützer, B Yadav, O Dufva, S Khan, L He, L Sellner, ...
Leukemia 32 (3), 774-787, 2018
872018
Prox1 promotes expansion of the colorectal cancer stem cell population to fuel tumor growth and ischemia resistance
Z Wiener, J Högström, V Hyvönen, AM Band, P Kallio, T Holopainen, ...
Cell reports 8 (6), 1943-1956, 2014
812014
Somatic MED12 mutations are associated with poor prognosis markers in chronic lymphocytic leukemia
K Kämpjärvi, TM Järvinen, T Heikkinen, AS Ruppert, L Senter, KW Hoag, ...
Oncotarget 6 (3), 1884, 2015
622015
Genome-scale screens identify factors regulating tumor cell responses to natural killer cells
M Sheffer, E Lowry, N Beelen, M Borah, SNA Amara, CC Mader, JA Roth, ...
Nature Genetics 53 (8), 1196-1206, 2021
612021
Immune profiles in acute myeloid leukemia bone marrow associate with patient age, T-cell receptor clonality, and survival
O Brück, O Dufva, H Hohtari, S Blom, R Turkki, M Ilander, P Kovanen, ...
Blood advances 4 (2), 274-286, 2020
492020
Erythroid/megakaryocytic differentiation confers BCL-XL dependency and venetoclax resistance in acute myeloid leukemia
H Kuusanmäki, O Dufva, M Vähä-Koskela, AM Leppä, J Huuhtanen, ...
Blood 141 (13), 1610-1625, 2023
402023
RUNX1 mutations in blast-phase chronic myeloid leukemia associate with distinct phenotypes, transcriptional profiles, and drug responses
S Adnan Awad, O Dufva, A Ianevski, B Ghimire, J Koski, P Maliniemi, ...
Leukemia 35 (4), 1087-1099, 2021
352021
Single-cell characterization of anti–LAG-3 and anti–PD-1 combination treatment in patients with melanoma
J Huuhtanen, H Kasanen, K Peltola, T Lönnberg, V Glumoff, O Brück, ...
The Journal of Clinical Investigation 133 (6), 2023
312023
Drug sensitivity profiling identifies potential therapies for lymphoproliferative disorders with overactive JAK/STAT3 signaling
H Kuusanmäki, O Dufva, E Parri, AJ van Adrichem, H Rajala, ...
Oncotarget 8 (57), 97516, 2017
302017
Nintedanib targets KIT D816V neoplastic cells derived from induced pluripotent stem cells of systemic mastocytosis
MAS Toledo, M Gatz, S Sontag, KV Gleixner, G Eisenwort, K Feldberg, ...
Blood, The Journal of the American Society of Hematology 137 (15), 2070-2084, 2021
292021
Ex vivo venetoclax sensitivity testing predicts treatment response in acute myeloid leukemia
H Kuusanmäki, S Kytölä, I Vänttinen, T Ruokoranta, A Ranta, ...
Haematologica 108 (7), 1768, 2023
222023
Data-driven characterization of molecular phenotypes across heterogeneous sample collections
J Mehtonen, P Pölönen, S Häyrynen, O Dufva, J Lin, T Liuksiala, ...
Nucleic acids research 47 (13), e76-e76, 2019
202019
Single-cell functional genomics reveals determinants of sensitivity and resistance to natural killer cells in blood cancers
O Dufva, S Gandolfi, J Huuhtanen, O Dashevsky, H Duàn, K Saeed, ...
Immunity 56 (12), 2816-2835. e13, 2023
102023
Targeting apoptosis pathways with BCL2 and MDM2 inhibitors in adult B-cell acute lymphoblastic leukemia
H Hohtari, M Kankainen, S Adnan-Awad, B Yadav, S Potdar, A Ianevski, ...
HemaSphere 6 (3), e701, 2022
102022
系统目前无法执行此操作,请稍后再试。
文章 1–20